The global computational biology market size was valued at USD 7.08 billion in 2025 and is projected to grow from USD 7.99 billion in 2026 to USD 21.07 billion by 2034, registering a CAGR of 12.88% during the forecast period from 2026 to 2034. North America dominated the computational biology market with a market share of 39.8% in 2025.
Computational biology is an interdisciplinary field that combines biology, computer science, mathematics, and statistics to study and analyze biological data. It uses computational tools and algorithms to understand complex biological processes, genes, proteins, cells, and organisms. Computational biology is widely used in areas such as genomics, drug discovery, disease research, personalized medicine, bioinformatics, and evolutionary studies. It helps researchers process large datasets, identify biological patterns, predict molecular interactions, and gain deeper insights into biological systems.
Download a Free Sample To learn more about this report,
Multimodal Foundation Models Integrate Multi-Omics Biological Data
Computational biology market analysis shows that the growing volume of transcriptomic and proteomic data is shifting computational platforms toward multimodal foundation models that analyze multiple biological layers together. A May 2026 study introduced CAPTAIN, a multimodal model trained on more than 4.2 million single cells with matched transcriptomic and surface-protein measurements, supporting cell-type annotation, protein prediction, and multi-omic integration. This transition enables researchers to build more complete cellular profiles and identify relationships that may remain hidden when each data type is analyzed separately.
Genome Foundation Models Enable DNA Sequence Prediction and Design
Large-scale genomic datasets are shifting computational biology toward foundation models capable of learning functional patterns across extensive DNA sequences. A 2025 Evo 2 study reported training on 9.3 trillion DNA base pairs spanning diverse organisms, with the model supporting variant-effect prediction and generation of novel DNA sequences. This transition expands computational biology from conventional genome interpretation toward sequence design and broader prediction of biological function.
AI-Assisted Drug Discovery and Spatial Omics Applications Drive Market
AI adoption across drug discovery workflows creates demand for computational platforms that support target identification, virtual screening, molecular interaction analysis, and candidate prioritization. Recent applications of AI in pharmaceutical R&D include structure prediction, virtual screening, and molecular design, expanding computational workloads across drug-development programs. Recursion’s Boltz-2, for example, supports molecular structure and binding-affinity prediction for large-scale drug discovery applications. These applications strengthen demand for computational biology software, data infrastructure, and specialized modelling services.
Wider use of spatial transcriptomics and spatial proteomics creates demand for tools that analyze cellular location, tissue architecture, and molecular interactions. Recent computational methods support spatial multi-omics integration, cell-niche identification, and spatial gene-expression analysis across complex biological samples. Cancer research provides an important application, with spatial analysis supporting biomarker discovery and characterization of tumor microenvironments. These analytical requirements expand demand for specialized computational biology platforms and data analysis services.
Computational Biology Skill Shortages and Experimental Translation Challenges Restrain Market Expansion
Limited availability of professionals with expertise in biology, bioinformatics, programming, and data science can make advanced computational platforms difficult to deploy effectively. Complex analytical workflows often require specialized knowledge for model development, data interpretation, and validation. This talent gap can reduce platform utilization and slow adoption across pharmaceutical, biotechnology, and research organizations.
Gaps between computational predictions and laboratory outcomes can create additional validation requirements before research organizations rely on computational biology tools for decision-making. Complex biological systems can produce results that require experimental confirmation, increasing development time and resource requirements. Such validation challenges can delay adoption and reduce the pace at which computational solutions move into routine research workflows.
Computational Toxicology and Synthetic Biology Design Platforms Offer Growth Opportunities
Pharmaceutical, biotechnology, chemical, and agrochemical companies can use computational toxicology platforms to assess safety risks before extensive laboratory testing. Certara’s ToxStudio, including its Libra DILI prediction tool, provides a commercial example of in silico safety assessment for drug development. Such platforms create revenue through software subscriptions, predictive modelling modules, and specialised safety-analysis services, contributing to computational biology market growth.
Synthetic biology companies and research organizations can use computational platforms to design biological systems, manage experimental data, and optimize engineering workflows. Benchling provides a commercial example, combining scientific data, computational tools, automation, and AI within biotechnology R&D workflows. These capabilities create revenue through platform subscriptions, workflow modules, data services, and enterprise integrations.
Restricted Genomic Data Access and Regulatory Uncertainty Hinder Growth
Controlled-access requirements, privacy protections, and institution-specific data-use procedures can restrict the datasets available to computational biology companies. NIH requirements introduced in 2025 place additional security obligations on organizations handling controlled-access genomic data, including when cloud providers are used. Such restrictions can reduce access to diverse datasets needed for model development and make commercial data partnerships more difficult.
Unclear regulatory pathways can make it difficult for companies to determine the validation, documentation, and compliance requirements needed before computational tools enter clinical workflows. A 2026 analysis of translational bioinformatics identified regulatory uncertainty, fragmented data access, and implementation infrastructure as major barriers to clinical adoption. These uncertainties can lengthen commercialization timelines and increase the resources required to bring products to market.
The drug discovery and disease modeling segment accounted for a share of 34.7% in 2025, due to its ability to accelerate target identification, analyze complex biological interactions, improve disease understanding, and support more efficient drug development processes.
The human body simulation software segment is expected to grow at a CAGR of 18.73% during the forecast period 2026-2034, driven by its ability to model physiological processes, support virtual testing, improve prediction of treatment responses, and reduce reliance on conventional experimental approaches. The cellular and biological simulation, preclinical drug development, and clinical trials segments are also expected to support market growth through computational modeling, virtual experimentation, drug candidate evaluation, and clinical research applications.
Request Customizationto receive a tailored report.
The analysis software and services segment accounted for a share of 44.3% in 2025 and is expected to grow at a CAGR of 18.29% during the forecast period 2026-2034, owing to its ability to support complex biological data analysis, genomic and molecular research, disease modeling, and efficient interpretation of large-scale datasets.
The databases and infrastructure (hardware) segments are also expected to support market growth through access to structured biological datasets, high-performance computing capabilities, data storage, and computational resources required for advanced biological research.
The in-house segment accounted for a share of 57.6% in 2025, supported by greater control over sensitive research data, direct access to specialized computational resources, and the ability to customize workflows according to internal research requirements.
The contract segment is expected to grow at a CAGR of 18.54% during the forecast period 2026-2034, propelled by access to specialized computational expertise, flexible research capabilities, cost-efficient outsourcing, and the ability to handle complex biological data analysis without extensive in-house infrastructure.
The industry and commercials segment accounted for a share of 61.3% in 2025 and is expected to grow at a CAGR of 18.18% during the forecast period 2026-2034, due to extensive use of computational biology for drug discovery, genomic analysis, biomarker research, and data-driven biological research across commercial organizations.
The academics segment is also expected to support market growth through computational research, biological data analysis, simulation studies, and the development of new methodologies across universities and research institutions.
Speak to an Analystto discuss market opportunities.
The North America computational biology market accounted for the largest regional share of 39.8% in 2025, while the U.S. National Institutes of Health’s 2025-2030 Strategic Plan for Data Science prioritizes new opportunities in computational methods and artificial intelligence, alongside expanded biomedical data infrastructure, supporting continued adoption of computational biology technologies.
The U.S. computational biology market is supported by the NIH BioGenesis Mission launched in 2026, which aims to double the pace of biomedical innovation within the next 5-10 years through AI, advanced computing, and data-driven research, while the Canadian computational biology market is supported by the 2025 Canadian Genomics Strategy, backed by $175.1 million in federal funding over seven years to strengthen genomics commercialization, data access, and computational biology capabilities.
Unlock Regional Insightsto access country-level data, & regional trends.
The Europe computational biology market is expected to grow at a CAGR of 18.91% during the forecast period 2026-2034, showcasing the fastest-growing regional market, while the European Commission’s 2025 life sciences strategy targets making Europe the world’s most attractive location for life sciences by 2030, with measures to accelerate innovation, market access, and technology adoption.
The U.K. computational biology market is supported by plans for Genomics England to host more than 500,000 genomes by 2030 and for up to 5 million participants to be enrolled in Our Future Health, while the Germany computational biology market is supported by the European Health Data Space framework, with secondary use of genomic data becoming applicable from 2031; the France computational biology market is supported by the 2025-2030 national rare-disease plan, which emphasizes genomics, precision medicine, and stronger use of health data and AI for research.
The Asia Pacific computational biology market accounted for a regional share of 22.4% in 2025, while China’s 2025 “AI Plus” action plan targets broad AI integration by 2030 and specifically calls for AI-driven scientific discovery, intelligent upgrades of research infrastructure, and high-quality scientific datasets, supporting the expansion of computational approaches in life sciences.
The Japan computational biology market is supported by the 2025 Integrated Innovation Strategy, which prioritizes AI, biotechnology, health and medicine, and data-driven research; the China computational biology market is supported by its 2030 AI-integration target; the South Korea computational biology market is supported by a 2030 plan to develop AI-driven biotechnology models across five areas, including drug discovery and biomanufacturing; and the India computational biology market is supported by a projected bioeconomy of $392 billion by 2030, with computational biology identified as a backbone of national biotechnology infrastructure.
The computational biology market is moderately fragmented, with life-science software companies, bioinformatics providers, genomics technology firms, computational drug-discovery companies, AI-driven biotechnology firms, and specialized research-platform providers competing across drug discovery, genomics, molecular modeling, and biological data analysis. Thermo Fisher Scientific, Illumina, QIAGEN, Danaher Corporation, and Schrödinger are among the leading players in the computational biology market, collectively accounting for an estimated 35-40% of the global computational biology market share.
Established players compete primarily on platform breadth, computational accuracy, validated algorithms, data resources, cloud capabilities, enterprise integration, and global customer networks, while emerging players in the Computational Biology Market ecosystem compete through AI-native models, specialized biological applications, multimodal data integration, automated workflows, scalable computing, and application-specific solutions. The competitive structure includes both broad life-science technology providers and specialized AI-driven platforms, with recent academic reviews highlighting approaches spanning generative chemistry, phenomics, knowledge-graph systems, and physics-based machine learning.
June 2026: Chai Discovery signed a license agreement with Pfizer, enabling Pfizer to deploy Chai’s AI platform and gain early access to the Chai-3 model.
May 2026: QIAGEN partnered with NVIDIA to integrate NVIDIA BioNeMo and accelerated computing with QIAGEN Digital Insights’ curated bioinformatics knowledge bases.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Organ Preservation Market Size, Share, Growth, Analysis, Report, 2034
Bacteriophage Market Size, Share, Growth, Analysis, 2034
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Biobanking Market Size, Share, Growth, 2034
Cell Therapy Manufacturing Market Size, Share, Growth, 2034
Clinical Oncology Next Generation Sequencing Market Size, 2034
We are featured on:
sales@straitsresearch.com